If you are interested in learning more about this study, please call or email the contact person below
|Title||A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) GS-US-384-1944|
|Description||The study visits will be in downtown Buffalo.
If you are interested in this study, please contact the study coordinator below.
|Objective||The purpose of this study is to see if selonsertib is safe, well tolerated, and whether it can reduce fibrosis and associated complications in subjects with cirrhosis fibrosis due to NASH.
Keywords: NASH, Non-alcoholic Steatohepatitis, liver, fibrosis, cirrhosis
|Principal Investigator||TALAL, ANDREW|
|Key Eligibility|| Nonalcoholic Steatohepatitis (NASH)
|Disease Group||Digestive System; Liver Diseases|
|Treatment||selonsertib (SEL; GS-4997)|